Meeting
2020 ASCO Virtual Scientific Program
Survival of subjects with recurrent glioblastoma receiving intratumoral administration of controlled IL-12 with limited exposure to dexamethasone.
Authors
Rimas Vincas Lukas
Northwestern Memorial Hospital, Chicago, IL
Rimas Vincas Lukas , Sylvia Christine Kurz , John Yu , Joseph C. Landolfi , Ganesh Rao , Christina Amidei , Jill Yannetti Buck , Nira Hadar , Taylor Estupinan , John Miao , John W. Loewy , Yunxia Wang , Nathan A. Demars , Arnold Bruce Gelb , Laurence JN Cooper
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT03679754
Citation
J Clin Oncol 38: 2020 (suppl; abstr 2564)
DOI
10.1200/JCO.2020.38.15_suppl.2564
Abstract #
2564
Poster Bd #
55
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Evaluation of controlled IL-12 as monotherapy in subjects with recurrent GBM.
First Author: Rimas Vincas Lukas
Poster
2019 ASCO Annual Meeting
Evaluation of controlled IL-12 in combination with a PD-1 inhibitor in subjects with recurrent glioblastoma.
First Author: E. Antonio Chiocca
Poster
2016 ASCO Annual Meeting
Effect of controlled intratumoral viral delivery of Ad-RTS-hIL-12 + oral veledimex in subjects with recurrent or progressive glioma.
First Author: Francois M. Lebel
Poster
2022 ASCO Annual Meeting
Preliminary results of a phase II study of retifanlimab (PD-1 inhibitor) plus or minus epacadostat (IDO1 inhibitor) in combination with bevacizumab and hypofractionated radiotherapy for recurrent glioblastoma: NCT03532295.
First Author: Jian Li Campian